9.6 Nonprescription Drug Labeling, Packaging & Repackaging

9.6 Nonprescription Drug Labeling, Packaging & Repackaging

Why this is tested: NABP Competency Statement 3.8 breaks non-prescription products into four sub-topics: dispensing or administration, labeling of non-prescription drugs and devices, packaging and repackaging of non-prescription drugs and behind-the-counter products, and dispensing-restricted non-prescription drugs. Candidates almost always study the last one (pseudoephedrine, exempt Schedule V) and skip the first three. This section covers the ones that get skipped.

---

1. What Counts as a Nonprescription Drug in Oklahoma

59 O.S. § 353.1 defines the term for Oklahoma purposes: "Nonprescription drugs" means medicines or drugs which are sold without a prescription and which are prepackaged and labeled for use by the consumer in accordance with federal and state law.

Two things follow from the definition:

• The product is prepackaged and labeled for the consumer by the manufacturer. Bulk product a pharmacy breaks down is a different regulatory animal — see repackaging below.
• "Sold without a prescription" describes the product's marketing status, not the transaction. The same OTC product can be dispensed on a prescription, and when it is, its labeling obligations change entirely.

---

2. The FDA Drug Facts Panel

FDA requires most OTC drug products to bear a standardized Drug Facts panel, in a fixed order and a legible standardized format:

+-------------------------------------------------------------+
| Drug Facts                                                  |
+-------------------------------------------------------------+
| Active ingredient(s) ................ (per dosage unit)     |
| Purpose ............................. (drug class/action)   |
| Uses ................................ (indications)         |
| Warnings ............................ Do not use / Ask a    |
|   doctor / Ask a doctor or pharmacist / When using this     |
|   product / Stop use and ask a doctor / Keep out of reach   |
|   of children / pregnancy-nursing statement                 |
| Directions .......................... (dosing by age)       |
| Other information ................... (storage etc.)        |
| Inactive ingredients ................ (alphabetical)        |
| Questions? .......................... (contact)             |
+-------------------------------------------------------------+

An OTC product that lacks a required warning, omits an accurate statement of quantity, or presents required information in a way not likely to be read and understood is misbranded under FDCA § 502 — the same standard covered in section 9.5. Note that the Drug Facts scheme is a labeling requirement; the same product can be perfectly formulated (not adulterated) and still be misbranded.

Devices sold without a prescription follow the parallel rule: adequate directions for use, and any FDA-required warnings, in terms likely to be read and understood by the ordinary individual.

---

3. When an OTC Product Acquires Prescription Labeling

This is the single most testable idea in this section.

Worked scenario. A patient brings in a prescription for "ibuprofen 200 mg, 1–2 tabs PO q6h PRN pain, #100" so that the cost is billed to their plan. Does the pharmacist simply hand over a manufacturer's bottle? No. Once dispensed pursuant to a prescription, the product is a dispensed prescription: it must bear the full prescription label, be entered into the patient record, receive prospective DUR, and trigger the counseling offer. The Drug Facts panel alone does not satisfy the state labeling rule.

---

4. Repackaging

Repackaging means transferring product from the manufacturer's container into another container for dispensing or distribution. Two distinct regulatory postures:

Repackaging by the dispensing pharmacy. A pharmacy that prepackages product in advance of dispensing (unit-dose cards for a long-term care facility, pre-count bottles for high-volume items) must ensure the repackaged container carries at minimum the drug name and strength, the manufacturer or distributor, the lot number, and a beyond-use date, and must maintain a record that lets any repackaged unit be traced back to the manufacturer's lot. This traceability is what makes a Class I recall executable — without a lot linkage, the pharmacy cannot identify which patients received the recalled lot.

Repackaging as a licensed activity. A firm that repackages for distribution is a repackager and holds its own Oklahoma license (fee $200 under OAC 535:1-11-1(8); authority 59 O.S. § 353.7(5)). Repackagers are also DSCSA trading partners and must pass transaction information and statements downstream. A retail pharmacy that begins repackaging product for sale to other entities has crossed out of dispensing into distribution and needs the appropriate license and — where it supplies drugs to another pharmacy or practitioner — a drug supplier permit with the record content required by OAC 535:15-7-2(c).

Beyond-use dating. USP guidance for repackaged solid oral dosage forms in a single-unit or unit-dose container is 1 year from the date of packaging or the manufacturer's expiration date, whichever is earlier, provided storage conditions are met. For a patient-specific prescription vial the outpatient default is 1 year from the date of dispensing or the manufacturer's expiration date, whichever is shorter — the rule covered in section 9.4.

---

5. Oklahoma's Pharmacist Prescribing Authority for OTC Compounding

Oklahoma grants an authority many states do not, and it appears twice in the law:

• 59 O.S. § 353.1c: "A pharmacist licensed by the State Board of Pharmacy may, in accordance with state and federal laws and rules, prescribe nonprescription drugs for the purposes of extemporaneous compounding or compounding for a known patient need in the practice area."
• OAC 535:15-10-1.1 implements it for the preparation of compounded drug products for OTC sale.

Read the boundary carefully: this is authority to prescribe nonprescription drugs, and only for compounding purposes — extemporaneous compounding or compounding for a known patient need in the practice area. It is not general pharmacist prescriptive authority, and it does not reach prescription drugs or controlled substances.

---

6. Behind-the-Counter & Dispensing-Restricted Nonprescription Drugs

Competency 3.8 also covers products that remain non-prescription but whose access is restricted. Oklahoma's principal examples:

Note the age discontinuity that shows up in exam items: the Schedule V and SLCP floors are 18, while the emergency contraception threshold in Oklahoma statute is 17. Do not average them into a single remembered number.